Asthma Clinical Research Studies

Interested in joining a clinical research trial?

Treatment options for asthma continue to evolve. Currently, our center has multiple asthma studies for treatments that include: investigational inhalers for children, generic versions of already marketed medication, oral medications as add-on therapy, injections as add-on therapy, and biologics (complicated molecules that are manufactured within a living organism). Each of these asthma studies offer unique treatment opportunities for patients with mild to extremely severe asthma. These medications are provided at absolutely no cost, with no insurance needed. You may also be reimbursed for your time and travel and will receive care from physicians affiliated with the Clinical Research Center of Alabama.

For more information on any of the following asthma studies, please contact Will O’Donnell by calling 205.209.4179 or emailing

Investigational Inhaler Study

Age 4-11


Teva is comparing Flovent to Advair in a new device. It used to be called Spiromax but is now used for ProAir RespiClick. It is supposed to be easier to use than the devices currently on the market because all you do is put the inhaler in your mouth and take a deep breath, there is no coordination required and that’s why they expect it to be easier for children. There is an equal chance to be in any of the four treatment arms: Flovent 50mcg, Flovent 10mcg, Advair 100/25mcg, and Placebo.

Oral Add-On Medication Study

Age 12+


This study is to evaluate the efficacy and safety of QAW039 (tablet) when added to the current standard of care treatment for severe asthmatic patients (meaning the patient stays on their current treatment). The screening period could last up to 2 weeks to assess eligibility. The run-in period will last a minimum of 2 weeks or a maximum of 6 weeks. The treatment period lasts 52 weeks and then there is a 4 week follow-up period. There are 12 total office visits and 6 phone call visits. Compensation is $100 for office visits and $25 for phone call visits.

Biologic - IV Treatment Study

Age 18+


GSK3772847 is a new type of study drug for subjects with asthma that is given by injection. GSK3772847 is a type of study drug called a monoclonal antibody that is made in the laboratory. It works by blocking a specific protein in the body called interleukin-33 which may be involved in asthma severity and inflammation of the lungs. The purpose of this study is to see how well GSK3772847 works.

Biologic Combination-Injection Study

Age 19 +

Sanofi-ACT 15102

The purpose of this study is to evaluate the safety, tolerability, and the effectiveness of SAR440430 alone or in combination with dupilumab for the treatment in patients with moderate-to-severe asthma who are not well controlled by inhaled corticosteroid (ICS) plus long-acting beta agonist (LABA) therapy.

Oral Medication

Age 12+


A 12 week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care therapy in patients with uncontrolled asthma.

Observational Study

Age 19+


The purpose of this study is to collect information to help us understand how doctors treat and manage people with severe asthma and how the health of people with severe asthma changes with those treatments. In this study, no specific treatment or research drug is given, but your normal care and assessments are recorded. The length of each patient’s participation will vary but the goal is to have patients involved for 3 or more years.

Investigational Inhaler Study

Age 12+

Pearl Asthma

This study is to evaluate the efficacy of an investigational product or use in the treatment of asthma. This is an orally inhaled product called Glycopoyrronium Inhalation Aerosol (also known as GP metered dose inhaler (MDI) or PT001). A MDI is a handheld device that delivers a specific amount of medication to the lungs by inhaling through the mouth.

Become a Participant in our Asthma Studies

If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.